HSD3B7

Across TCGA pan-cancer cohorts, HSD3B7 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HSD3B7 data layer compared with 21 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HSD3B7 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated HSD3B7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where HSD3B7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	1.000	0.771	.015	8	view →
LUAD	DFS	Quartile	III,IV	0.993	0.465	.040	3	view →
CCRCC	DFS	Tertile	III,IV	1.000	0.763	.039	3	view →
LSCC	OS	Tertile	All	0.947	1.000	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

HSD3B7–PDAC (OS)

Open the PDAC breakdown →